Dermatology · Philadelphia, PA
NPI
1710902382
Since 2006
Specialty
Dermatology
Code 207N00000X
Group practices
1
Medicare group memberships
Hospitals
2
Hospital affiliations
3400 Spruce Street, 2 Rhodes Pavilion
Philadelphia, PA, 19104
Phone (215) 662-2737
Groups this clinician bills Medicare through
Medicare paid, 2024
$16K
325 services
Medicare patients, 2024
111
Average age 73
Drug cost, 2024
$2.8M
426 prescriptions
Company payments, 2025
$87K
From 11 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Joel M Gelfand was code 99214 (office e&m - established), 155 times for 93 patients. In total Joel M Gelfand billed 325 services in 16 codes, and Medicare paid $16K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2011-02-18.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Facility | 155 | 93 | $72.37 | $11K |
| 17003 Destruction Skin Lesion | Facility | 49 | 11 | $1.62 | $79.35 |
| 17000 Destruction Skin Lesion | Facility | 32 | 23 | $43.19 | $1,382 |
| 99213 Office E&M - Established | Facility | 22 | 18 | $45.99 | $1,012 |
| 11102 Skin Biopsy | Facility | 20 | 18 | $24.47 | $489 |
| 17110 Destruction Skin Lesion | Facility | 13 | 11 | $52.43 | $682 |
By year: 2022 $13K for 247 services; 2023 $15K for 313 services; 2024 $16K for 325 services.
Medicare prescription drug claims, 2024
In 2024, the drug Joel M Gelfand prescribed most often to Medicare patients was Skyrizi Pen (Risankizumab-Rzaa), with 64 prescriptions and refills. In total Joel M Gelfand wrote 426 Medicare prescriptions that cost $2.8M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Skyrizi Pen Risankizumab-Rzaa | 64 | 173 | 19 | $1.3M |
| Triamcinolone Acetonide Generic | 30 | 32 | 23 | $372 |
| Clobetasol Propionate Generic | 27 | 27 | 19 | $947 |
| Skyrizi Risankizumab-Rzaa | 26 | 73 | Under 11 | $519K |
| Vtama Tapinarof | 22 | 26 | 13 | $34K |
| Tremfya Guselkumab | 20 | 37 | Under 11 | $268K |
| Otezla Apremilast | 20 | 20 | Under 11 | $67K |
| Acitretin Generic | 19 | 37 | Under 11 | $7,350 |
| Ketoconazole Generic | 14 | 14 | Under 11 | $194 |
| Halobetasol Propionate Generic | 13 | 13 | Under 11 | $351 |
| Bimzelx Autoinjector Bimekizumab-Bkzx | 12 | 15 | Under 11 | $168K |
| Betamethasone Dipropionate Generic | 11 | 12 | Under 11 | $464 |
| Cosentyx Sensoready (2 Pens) Secukinumab | 11 | 11 | Under 11 | $89K |
Brand drugs: 228 claims; generic drugs: 198 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Joel M Gelfand $87K ($66K in general payments such as food, travel and fees and $21K for research) from 11 companies. The largest payer was Eli Lilly and Company with $24K.
| Company | Payments | Amount |
|---|---|---|
| Eli Lilly and Company LLY | 6 | $24K |
| Takeda Pharmaceuticals U.S.A., Inc. TAK | 3 | $13K |
| LEO Pharma Inc. | 8 | $13K |
| Janssen Scientific Affairs, LLC JNJ | 4 | $12K |
| Teva Pharmaceuticals USA, Inc. TEVA | 2 | $8,288 |
| Amgen Inc. AMGN | 15 | $5,672 |
| Boehringer Ingelheim International GmbH | 5 | $4,014 |
| Pfizer Inc. PFE | 1 | $3,560 |
| Janssen Biotech, Inc. JNJ | 9 | $3,219 |
| Arcutis Biotherapeutics, Inc. ARQT | 1 | $950 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.